© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Health and Biotech

Top Section/Ad

Top Section/Ad

Most recent


Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad

More articles/Ad

More articles

  • India is facing yet another upheaval as the Covid-19 pandemic makes its way through the country. Capital markets activity has all but come to a halt. There are few bright spots, but bankers are focusing on innovation and thinking long term. By Rashmi Kumar
  • The Covid-19 pandemic has forced Asia’s debt issuers to confront a fundamental question: how can they raise money in these turbulent times? Bond bankers are scrambling to find the best solutions for their clients as they position themselves for when the market reopens. Morgan Davis reports.
  • It should come as little surprise that the Covid-19 pandemic has led to a sharp repricing of Chinese bonds in the onshore and offshore markets. What might be a surprise is that the two markets have gone in different directions. Rebecca Feng reports
  • Few bankers, if any, will emerge from the coronavirus unaffected. But leveraged finance bankers have reason to believe they will be able to generate new deals from the chaos — even if they lose a few old ones along the way. Pan Yue reports.
  • Chinese oil and gas company MIE Holdings Corp has missed interest payment on a dollar bond during the grace period, triggering cross-defaults on its loan facilities. The firm has been hit hard by tumbling oil prices this year, putting pressure on its liquidity.
  • More and more Chinese issuers are using the Covid-19 pandemic as a convenient excuse to justify missed or delayed payments of bonds. The trend needs to stop.